-
1.发明公开
公开(公告)号：EP1667721A2
公开(公告)日：2006-06-14
申请号：EP04765555.0
申请日：2004-09-23
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BOLD, Guido , BRUEGGEN, Josef, Bernhard , HUANG, Jerry, Min-Jian , KINDER, Frederick, Ray , LANE, Heidi , LATOUR, Elisabeth, Jeanne , MANLEY, Paul, William , WOOD, Jeanette, Marjorie
CPC分类号： A61K45/06
摘要： The invention relates to a combination therapy for treating patients suffering from diseases characterized by cell proliferation and infiltration of inflammatory cells, coronary diseases, hypertension, renal diseases, diabetes, or ocular diseases and conditions. The patient is treated with a combination of: (a) a VEGF inhibitor compound; and (b) one or more second therapeutic agents selected from the group consisting of: i. angiostatic steroids; ii. photosensitizers; iii. implants containing corticosteroids; iv. AT1 receptor antagonists; V. ACE inhibitors; vi. cyclooxygenase inhibitors; vii. IGF-IR inhibitors; viii. mTOR kinase inhibitors; ix. somatostatin receptor antagonists; X. P13K inhibitors; A. Raf kinase inhibitors; xii. PKC inhibitors; xiii. integrin antagonists; xiv. endogenous anti-anglogenic molecules; and xv. PEDF and analogs.
-
2.发明公开COMBINATIONS COMPRISING EPOTHILONES AND PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USES THEREOF 有权与埃博霉素和蛋白酪氨酸激酶抑制剂和使用它们的组合PHARAMAZEUTISCHE
公开(公告)号：EP1819331A1
公开(公告)日：2007-08-22
申请号：EP05852316.8
申请日：2005-11-28
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
发明人： HUANG, Jerry, Min-Jian , JOHRI, Anandhi, Ranganathan , LINNARTZ, Ronald, Richard , MCSHEEHY, Paul, M., J.
IPC分类号： A61K31/426 , A61K31/519 , A61K31/436 , A61P35/00
CPC分类号： A61K45/06 , A61K31/426 , A61K31/436 , A61K31/519 , A61K2300/00
摘要： The invention relates to a combination which comprises: (a) an epothilone; and (b) a protein tyrosine kinase inhibitor; and optionally (c) a derivative of rapamycin; for simultaneous, separate or sequential use, in particular, for the delay of progression or treatment of a proliferative disease, especially cancer.
-
3.发明授权COMBINATIONS COMPRISING EPOTHILONES AND PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USES THEREOF 有权与埃博霉素和蛋白酪氨酸激酶抑制剂和使用它们的组合PHARAMAZEUTISCHE
公开(公告)号：EP1819331B1
公开(公告)日：2009-10-14
申请号：EP05852316.8
申请日：2005-11-28
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
发明人： HUANG, Jerry, Min-Jian , JOHRI, Anandhi, Ranganathan , LINNARTZ, Ronald, Richard , MCSHEEHY, Paul, M., J.
IPC分类号： A61K31/426 , A61K31/519 , A61K31/436 , A61P35/00
CPC分类号： A61K45/06 , A61K31/426 , A61K31/436 , A61K31/519 , A61K2300/00
摘要： The invention relates to a combination which comprises: (a) an epothilone; and (b) a protein tyrosine kinase inhibitor; and optionally (c) a derivative of rapamycin; for simultaneous, separate or sequential use, in particular, for the delay of progression or treatment of a proliferative disease, especially cancer.
-
4.发明公开
公开(公告)号：EP1682181A2
公开(公告)日：2006-07-26
申请号：EP04765542.8
申请日：2004-09-23
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BOLD, Guido , BRUEGGEN, Josef, Bernhard , HUANG, Jerry, Min-Jian , KINDER, Frederick, Ray, Jr. , LANE, Heidi , LATOUR, Elisabeth, Jeanne , MANLEY, Paul, William , WOOD, Jeanette, Marjorie
IPC分类号： A61K45/06 , A61K31/502
CPC分类号： A61K45/06 , A61K31/502 , A61K2300/00
摘要： The present invention relates to a combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis. The patient is treated with a VEGF inhibitor compound; and one or more chemotherapeutic agents.
-
-
-
搜索结果
4 条记录 (耗时 0.012 秒)
